This guideline was prepared by a task force nominated by the Executive Board of the European Association for Neuro-Oncology (EANO) in cooperation with the Brain Tumor Group of the European Organisation for Research and Treatment of Cancer in 2016. The task force represents the disciplines involved in the diagnosis and care of patients with glioma and reflects the multinational character of EANO. We used PubMed and the search terms “glioma”, “anaplastic”, “astrocytoma”, “oligodendroglioma”,
ReviewEuropean Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
Introduction
The European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas follows the revision of the fourth edition of WHO classification of tumours of the central nervous system1 and builds on previous guidelines.2, 3 The guideline covers adult astrocytic and oligodendroglial gliomas of WHO grades II–IV, including glioblastomas, and variants of these tumours, and discusses prevention, early diagnosis and screening, histological and molecular diagnostics, therapy, and follow-up. However, the guideline does not address differential diagnosis, adverse effects of treatment, or supportive or palliative care.
Section snippets
Prevention, early diagnosis, and screening
The annual incidence of gliomas, including glioblastoma, is around six cases per 100 000 individuals worldwide. Serum markers for early detection have not been identified. Brain MRI has the highest sensitivity for the detection of small tumours. Gliomas can evolve rapidly over several weeks or months, presenting challenges for population-based prevention or early intervention. Screening is therefore limited to individuals at genetic risk—eg, patients with neurofibromatosis type I, Turcot
Prognostic factors
Younger age and better performance status are important positive, therapy-independent prognostic factors across glioma entities, and extent of resection is an important therapy-dependent prognostic factor (figure 2). Molecular markers that favour longer survival, such as IDH mutation and 1p/19q codeletion, are now at the core of the WHO classification and define more homogeneous diagnostic and prognostic entities.1, 26
Surgical therapy
Beyond a histological diagnosis, the goal of surgery is to remove as much of
Search strategy and selection criteria
References (87)
- et al.
EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma
Lancet Oncol
(2014) - et al.
“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician
J Psychiatr Res
(1975) - et al.
Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up
Lancet Neurol
(2009) - et al.
Epilepsy meets cancer: when, why, and what to do about it?
Lancet Oncol
(2012) - et al.
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Lancet Oncol
(2012) - et al.
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Lancet Oncol
(2012) - et al.
Molecular neuro-oncology in clinical practice: a new horizon
Lancet Oncol
(2013) - et al.
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial
Lancet Oncol
(2006) - et al.
Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review
Radiother Oncol
(2002) - et al.
ESTRO-ACROP guideline “target delineation of glioblastomas”
Radiother Oncol
(2016)
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial
Lancet
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Lancet Oncol
Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy
Ann Oncol
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Lancet Oncol
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
Lancet Oncol
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality
Eur J Cancer
New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951
Eur J Cancer
The 2016 World Health Organization classification of tumors of the central nervous system: a summary
Acta Neuropathol
Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force
Eur J Neurol
Understanding inherited genetic risk of adult glioma-a review
Neurooncol Pract
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment
J Am Geriatr Soc
Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma
J Clin Oncol
Consensus recommendations for a standardized brain tumor imaging protocol in clinical trials
Neuro Oncol
Response assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas
Neuro Oncol
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group
J Clin Oncol
Surgeon volume and 30 day mortality for brain tumours in England
Br J Cancer
The risk of haemorrhage after image guided stereotactic biopsy of intra-axial brain tumours—a prospective study
Acta Neurochir (Wien)
Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma
N Engl J Med
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
N Engl J Med
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation
Neurology
Short-course radiation plus temozolomide in elderly patients with glioblastoma
N Engl J Med
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951
J Clin Oncol
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402
J Clin Oncol
Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma
Acta Neuropathol
Gliomatosis cerebri: no evidence for a separate brain tumor entity
Acta Neuropathol
Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis
J Clin Oncol
Brain tumour cells interconnect to a functional and resistant network
Nature
Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) working group
Neurosurgery
Neuro-Oncology Working Group (NOA)-01 trial of ACNU/VM26 versus ACNU/Ara-C chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma
J Clin Oncol
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors
Neuro Oncol
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide
Neuro Oncol
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma
Neuro Oncol
Cited by (781)
Impact of tissue-agnostic approvals on management of primary brain tumors
2024, Trends in CancerAntibody Conjugated Nano-Enabled Drug Delivery Systems Against Brain Tumors
2024, Journal of Pharmaceutical SciencesThe impact of fluorine-18-fluoroethyltyrosine positron emission tomography scan timing on radiotherapy planning in newly diagnosed patients with glioblastoma
2024, Physics and Imaging in Radiation Oncology